Houston, United States
EndoQuest Robotics, founded in 2017, is at the forefront of developing cutting-edge endoluminal robotic technologies aimed at revolutionizing gastrointestinal (GI) medicine. Upholding its slogan, "Making endoluminal, scar-free surgery a reality," the company is committed to providing groundbreaking solutions for minimally invasive procedures.
Their proprietary robotic system, currently under development and pending FDA clearance, is designed to perform surgeries via the body's natural orifices, significantly minimizing invasiveness. This technology not only aims for precision and flexibility but also strives to elevate patient outcomes and redefine surgical standards.
Headquartered in the United States, EndoQuest has garnered substantial interest from the investment community. The company recently secured a $42.00M Series C funding round on 04 December 2023, attracting notable investors such as McNair Interests, Puma Venture Capital, and CE-Ventures. This investment underscores confidence in their innovative approach and potential market impact.
